

Eligibility Checklist for Post-Discharge VTE Prophylaxis

Consider prescribing **rivaroxaban 10 mg PO daily** for a total of 31-39 days (including inpatient days) for patients who meet the following criteria.

For patients aged >60 and hospitalized for ≥ 1 of the following acute medical conditions:

- Decompensated heart failure
- Respiratory insufficiency or COPD exacerbation
- Infectious or inflammatory disease
- Ischemic stroke with lower extremity paresis and reduced mobility

OR

For patients aged 40-59, hospitalized for ≥ 1 of the above acute medical illnesses

AND

Have ≥ 1 of the below additional VTE risk factor(s):

- Previous VTE or superficial vein thrombosis
- History of cancer
- History of NYHA Class III or IV heart failure
- Obesity (BMI >35)
- Inherited or acquired thrombophilia
- Current use of erythropoiesis-stimulating agent
- Current use of hormone therapy

Do not use if any of the following are present:

- Contraindications to anticoagulant prophylaxis
- Creatinine Clearance < 15 mL/min
- Concomitant combined P-gp and strong CYP3A4 inhibitors and inducers
- Pregnant or breastfeeding
- **Currently on dual antiplatelet therapy (DAPT)**
- **Active bleeding within the last 3 months**
- **Gastroduodenal ulcers within the last 3 months**
- **History of bronchiectasis, pulmonary cavitation, or pulmonary hemorrhage**
- **Active cancer (undergoing acute in-hospital cancer treatment)**

**Bolded exclusion criteria have been associated with increased fatal or major bleeding events*